Walgreens’ Rx Savings Club tops 1 million
DEERFIELD, Ill. Walgreens announced Wednesday that it has enrolled more than one million pharmacy patients in the Walgreens Prescription Savings Club.
The club offers discounts on more than 5,000 branded and generic medications, including a 90-day supply of more than 400 generic drugs for less than $1 per week, the company noted. Discounts through club membership extend to every drug category, “with significant savings on some of the most commonly prescribed medications, including treatments for pain, asthma, blood pressure, cholesterol, diabetes and women’s health,” Walgreens reported.
The club also covers preventive and lifestyle drugs not covered under most insurance plans, such as weight management, smoking cessation, family planning and sexual health.
Walgreens launched the program last fall, and reports steady growth “driven primarily by one-on-one pharmacist recommendations.” The chain has bolstered consumer awareness in recent weeks through advertising and marketing support.
“This plan continues to attract so many people because it truly hits the mark with its breadth of coverage addressing a wide array of prescription needs,” said Walgreens senior vice president of pharmacy services Kermit Crawford. “Add the convenience of 6,400 locations and the security of being able to use one pharmacy for every prescription and the decision to join the club is easy.”
Teva’s Azilect slows Parkinson’s disease in trials
WASHINGTON Results from a Phase III clinical trial have shown that Teva Pharmaceutical’s Azilect 1-mg tablets can slow the progression of the disease, the drug maker announced.
Researchers gave 1,176 Parkinson’s disease patients daily 1- to 2-mg doses of Azilect for 18 months or a placebo for the first nine months and the drug for the second nine months.
Patients who took the 1-mg dose of Azilect showed significant improvement compared with patients in the placebo group.
The Food and Drug Administration approved Azilect in May 2006 as a monotherapy for early-stage ParkinsonOs disease and as an adjunct therapy to levodopa in moderate-to-advanced stages of the disease.
The drug, known generically as rasagiline mesylate, is available in 30 countries. Danish drug maker Lundbeck markets it in Europe, and both companies plan to co-promote it in the United Kingdom, Germany and France.
Taro to ask for extension on Sun Pharmaceuticals’ offer
TEL AVIV,, Israel Taro Pharmaceutical Industries has said it will appeal to Israel’s Supreme Court to contest a ruling in the Tel Aviv District Court regarding India-based Sun Pharmaceuticals’ offer to acquire the Israeli generic drug maker.
The District Court judge had called Taro’s demand for a tender offer from Sun disingenuous, considering Taro’s acceptance of the offer a year ago.
Taro plans to ask the Supreme Court to extend the deadline for Sun’s offer, which was Tuesday at 5 p.m.